Swaminathan Murugappan
Chief Medical Officer - Consulting @Triumvira Immunologics, Inc
Signup · Get unlimited contacts
WORK HISTORY
Chief Medical Officer - Consulting @Triumvira Immunologics, Inc
San Francisco, CA, US
As a consulting chief medical officer, I led the clinical development strategy for the CLDN18.2 TAC CART program, successfully completing the Phase 1 dose escalation study across three dose levels. Directed enrollment, data analysis, and clinical operations, culminating in a successful presentation at ASCO GI 2025. I collaborated closely with senior leadership including the CEO, CSO, and R&D teams while providing regular updates to the Board of Directors on study progress and strategic direction. Additionally supported key business development initiatives throughout the program lifecycle.
EDUCATION
MIT Sloan Executive Education
Certification, Artificial Intelligence in Pharma and Biotech
University of Washington
Fellow, Hematology and Oncology
Madras Medical College - India
M.D, Medicine
Texas McCombs School of Business
Immersion Program, Decision Science and Artifical Intelligence
Temple University - Lewis Katz School of Medicine
Ph.D, Physiology
Texas McCombs School of Business
Post Graduate Program, Artificial Intelligence and Machine Learning for Business Applications
Drexel University
Resident, Internal Medicine
ABOUT SWAMINATHAN MURUGAPPAN
PROFESSIONAL SUMMARY:Board-certified hematologist-oncologist and physician-scientist with 15 years of experience driving oncology drug development from discovery through global commercialization across innovative platforms including CAR-T cell therapy, T-cell engagers, oncolytic viruses, mRNA therapeutics, and monoclonal antibodies. Successfully led and supported regulatory approvals for three marketed products (Vectibix®, ImLygic®, Tecartus®) and INDs for CART and T-cell engagers. Proven expertise in clinical trial design and execution (Phase 1-3), regulatory strategy, cross-functional leadership, and commercial launch planning. Currently serves as Founder and Chief Medical Officer of Trident Bio Consulting, providing strategic guidance to biotech and pharma clients developing transformational hematology-oncology therapies. AI enthusiast motivated to incorporate technology in clinical drug development.AREAS OF EXPERTISE:Clinical Development: Phase 1-3 trial design and execution, IND/BLA preparation and filing, regulatory strategy (FDA, EMA, Health Canada, MHRA, TGA, PMDA, CFDA), dose-level safety meetings, data monitoring committees, clinical operationsTherapeutic Platforms: CAR-T cell therapy, T-cell engagers (BiTE), bi-specific antibodies, oncolytic viruses, mRNA therapeutics, monoclonal antibodies, antibody-drug conjugates (ADCs)Tumor Expertise: Metastatic colorectal cancer, non-small cell lung cancer, small cell lung cancer, non-Hodgkin lymphoma, multiple myeloma, gastric/gastroesophageal cancer, hepatocellular carcinoma, pancreatic cancer, ovarian cancer, prostate cancerLeadership: Cross-functional team leadership, P&L management ($15M+ budgets), business development and fundraising, KOL engagement, Board of Directors interactions, talent development and team building
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.